Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • PI3K
    (5)
  • PI4K
    (2)
  • mTOR
    (2)
  • Apoptosis
    (1)
  • DNA-PK
    (1)
  • FLT
    (1)
  • S6 Kinase
    (1)
  • c-Fms
    (1)
  • Others
    (2)
Filter
Search Result
Results for "

pi3kα in 4

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | Inhibitors_Agonists
PI3Kα-IN-4
PI3Kα-IN-4
T355272322293-83-2
PI3Kα-IN-4 is a potent, selective, and orally active PI3Kα inhibitor with an IC50 of 1.8 nM, demonstrating antitumor activity [1].
  • Inquiry Price
6-8 weeks
Size
QTY
(S)-PI3Kα-IN-4
(S)-PI3Kα-IN-4
T354882322293-84-3
(S)-PI3Kα-IN-4, a potent inhibitor of PI3Kα with an IC50 of 2.3 nM, demonstrates 38.3-, 4.25-, and 4.93-fold selectivity over PI3Kβ, PI3Kδ, and PI3Kγ, respectively, and is suitable for cancer research[1]. (S)-PI3Kα-IN-4 (compound 11) is a quinazolin-4(3H)-one derivative with 2-substituted-N-methylpropanamide substitution[1].
  • Inquiry Price
6-8 weeks
Size
QTY
PI4KIIIbeta-IN-10
T124681881233-39-1
PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 value of 3.6 nM.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
PI4KIIIbeta-IN-9
T124691429624-84-9
PI4KIIIbeta-IN-9 is a potent inhibitor of PI4KIIIβ [IC50 of 7 nM].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
AMG 511
T142141253573-53-3
AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks (Kis of 4 nM, 6 nM, 2 nM, and 1 nM for PI3Kα, β, δ, and γ, respectively), exhibiting anti-tumor activity in a mouse glioblastoma xenograft model[1]. AMG 511 significantly suppresses PI3K signaling as indicated by a decrease in p-Akt (Ser473).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Bimiralisib
PQR309, PI3K-IN-2, 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
T22651225037-39-7
Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K mTOR. Activation of the PI3K mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.
  • Inquiry Price
Size
QTY
onatasertib
CC-223, CC223, CC 223
T33511228013-30-6
Onatasertib (CC223) is an orally available mTOR inhibitor with potential antitumor activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Onatasertib is a potent mTOR kinase inhibitor (IC50: 16 nM), with >150-fold sensitivity than the related lipid kinase PI3Kα (IC50: 4 μM).
  • Inquiry Price
Size
QTY
PI3Kα-IN-17
T871612935973-28-5
PI3Kα-IN-17 (example 4), a potent PI3K α inhibitor [1], effectively targets the enzyme.
  • Inquiry Price
10-14 weeks
Size
QTY